We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.
- Authors
Jordan, V Craig; Curpan, Ramona; Maximov, Philipp Y
- Abstract
The consistent reports of mutations at Asp538 and Tyr537 in helix 12 of the ligand-binding domain (LBD) of estrogen receptors (ERs) from antihormone-resistant breast cancer metastases constitute an important advance. The mutant amino acids interact with an anchor amino acid, Asp351, to close the LBD, thereby creating a ligand-free constitutively activated ER. Amino acids Asp 538, Tyr 537, and Asp 351 are known to play a role in either the turnover of ER, the antiestrogenic activity of the ER complex, or the estrogen-like actions of selective ER modulators. A unifying mechanism of action for these amino acids to enhance ER gene activation and growth response is presented. There is a range of mutations described in metastases vs low to zero in primary disease, so the new knowledge is of clinical relevance, thereby confirming an additional mechanism of acquired resistance to antihormone therapy through cell population selection pressure and enrichment during treatment. Circulating tumor cells containing ER mutations can be cultured ex vivo, and tumor tissues can be grown as patient-derived xenografts to add a new dimension for testing drug susceptibility for future drug discovery.
- Subjects
ASPARTIC acid; BREAST tumors; GENETIC mutation; PROTEINS; TYROSINE; XENOGRAFTS; SELECTIVE estrogen receptor modulators; PHARMACODYNAMICS
- Publication
JNCI: Journal of the National Cancer Institute, 2015, Vol 107, Issue 6, pdjv075
- ISSN
0027-8874
- Publication type
journal article
- DOI
10.1093/jnci/djv075